Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies
| Autor: | Fausto Petrelli, Veronica Lonati, Francesca Trevisan, Silvia Seghezzi, Giovanna Moleri, Gianluca Tomasello, Alice Indini, Michele Ghidini, Roberta Bukovec, Luca Turati, Alberto Zaniboni, Antonio Ghidini |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cervical cancer
Oncology medicine.medical_specialty General Immunology and Microbiology business.industry viruses Hazard ratio Cancer virus diseases Disease General Medicine Cochrane Library biochemical phenomena metabolism and nutrition medicine.disease digestive system diseases General Biochemistry Genetics and Molecular Biology Renal cell carcinoma Internal medicine Meta-analysis medicine Stage (cooking) General Pharmacology Toxicology and Pharmaceutics business |
| Zdroj: | F1000Research. 10:423 |
| ISSN: | 2046-1402 |
| DOI: | 10.12688/f1000research.52546.4 |
| Popis: | Background: The modern concept of oligometastatic (OM) state has been initially developed to describe patients with a low burden of disease and with a potential for cure with local ablative treatments. We systematically assessed the risk of death and relapse of oligometastatic (OM) cancers compared to cancers with more diffuse metastatic spread, through a meta-analysis of published data. Methods: PubMed, the Cochrane Library, and EMBASE were searched for studies reporting prognosis of patients with OM solid tumors. Risk of death and relapse were extracted and pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI). The primary outcome of the study refers to overall mortality in OM vs. polymetastatic (PM) patients. Results. Mortality and relapse associated with OM state in patients with cancer were evaluated among 104,234 participants (n=173 studies). Progression-free survival was better in patients with OM disease (hazard ratio [HR] = 0.62, 95% CI 0.57–0.68; P Conclusions. Patients with oligometastases have a significantly better prognosis than those with more widespread stage IV tumors. In OM cancer patients a personalized approach should be pursued. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|